

# Executive Summary



## Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline

James D. Douketis, MD, FCCP; Alex C. Spyropoulos, MD, FCCP; M. Hassan Murad, MD, MPH; Juan I. Arcelus, MD; William E. Dager, PharmD; Andrew S. Dunn, MD, MPH; Ramiz A. Fargo, MD, FCCP; Jerrold H. Levy, MD; C. Marc Samama, MD; Sahrish H. Shah, MBBS; Matthew W. Sherwood, MD; Alfonso J. Tafur, MD; Liang V. Tang, MD; and Lisa K. Moores, MD, FCCP

**BACKGROUND:** The American College of Chest Physicians Clinical Practice Guideline on the Perioperative Management of Antithrombotic Therapy addresses 43 Patients-Interventions-Comparators-Outcomes (PICO) questions related to the perioperative management of patients who are receiving long-term oral anticoagulant or antiplatelet therapy and require an elective surgery/procedure. This guideline is separated into four broad categories, encompassing the management of patients who are receiving: (1) a vitamin K antagonist (VKA), mainly warfarin; (2) if receiving a VKA, the use of perioperative heparin bridging, typically with a low-molecular-weight heparin; (3) a direct oral anticoagulant (DOAC); and (4) an antiplatelet drug.

**METHODS:** Strong or conditional practice recommendations are generated based on high, moderate, low, and very low certainty of evidence using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology for clinical practice guidelines.

**RESULTS:** A multidisciplinary panel generated 44 guideline recommendations for the perioperative management of VKAs, heparin bridging, DOACs, and antiplatelet drugs, of which two are strong recommendations: (1) against the use of heparin bridging in patients with atrial fibrillation; and (2) continuation of VKA therapy in patients having a pacemaker or internal cardiac defibrillator implantation. There are separate recommendations on the perioperative management of patients who are undergoing minor procedures, comprising dental, dermatologic, ophthalmologic, pacemaker/internal cardiac defibrillator implantation, and GI (endoscopic) procedures.

**CONCLUSIONS:** Substantial new evidence has emerged since the 2012 iteration of these guidelines, especially to inform best practices for the perioperative management of patients who are receiving a VKA and may require heparin bridging, for the perioperative management of patients who are receiving a DOAC, and for patients who are receiving one or more antiplatelet drugs. Despite this new knowledge, uncertainty remains as to best practices for the majority of perioperative management questions. CHEST 2022; 162(5):1127-1139

**KEY WORDS:** antithrombotic therapy; perioperative care; surgery; thrombosis

**ABBREVIATIONS:** ASA = aspirin; ATE = arterial thromboembolism; CABG = coronary artery bypass graft; CHADS<sub>2</sub> = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack; CHA<sub>2</sub>DS<sub>2</sub>VASc = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease history, age ≥ 65

years, female sex; CrCl = creatinine clearance; DOAC = direct oral anticoagulant; GRADE = Grading of Recommendations, Assessment, Development, and Evaluation; ICD = internal cardiac defibrillator; INR = international normalized ratio; LMWH = low-molecular-weight heparin; PICO = Patients-Interventions-Comparators-Outcomes; UFH = unfractionated heparin; VKA = vitamin K antagonist

**Editor's Note:** The online supplement to this guideline [[https://journal.chestnet.org/article/S0012-3692\(22\)01359-9/fulltext](https://journal.chestnet.org/article/S0012-3692(22)01359-9/fulltext)] contains an expanded introduction and methods section with a full delineation of terminology, organization of the PICO questions in the guideline, panel selection, and description of conflict of interest management. For each PICO, the online supplement contains the evidence profile with complete summary of findings, additional comments, background information, evidence-to-decision description, and comparison with prior versions of the guideline.

The perioperative management of antithrombotic therapy encompasses patients who are receiving a vitamin K antagonist (VKA), a direct oral anticoagulant (DOAC), or an antiplatelet drug and require a surgery or invasive procedure. An estimated 10 to 12 million people are assessed worldwide annually for perioperative anticoagulant management.<sup>1-3</sup> Since 2008, the American College of Chest Physicians (CHEST) Antithrombotic Guidelines have dedicated chapters addressing the perioperative management of patients who are receiving

antithrombotic therapy.<sup>4,5</sup> The last iteration in 2012 addressed 11 Patients-Interventions-Comparators-Outcomes (PICO) questions that were separated into three domains, comprising perioperative management of VKAs, antiplatelet drugs, and heparin bridging.<sup>5</sup>

The CHEST Guidelines on Perioperative Antithrombotic Therapy on Perioperative Antithrombotic Therapy have expanded from previous iterations to address 43 PICO questions, with 44 associated recommendations. Overall, 39 of 43 recommendations achieved consensus in the first voting round, with the remainder achieving consensus in the second voting round. New domains that are addressed include the perioperative management of patients who are receiving a DOAC and those who are receiving a P2Y<sub>12</sub> inhibitor antiplatelet agent, as well as guidance on perioperative laboratory testing. Since the last iteration, new clinical trial data have emerged that inform the perioperative management of heparin bridging in patients who are receiving a VKA, the perioperative management of patients who are taking DOACs, and the perioperative management of patients taking antiplatelet drugs. The guideline statements are intended primarily for clinicians who manage patients on antithrombotic therapy in perioperative settings but may also inform researchers in selecting questions for future studies, as well as patients and policy makers who are involved in patient care path development. This guideline is the first addressing the topic of the perioperative antithrombotic management that will be regularly updated as new evidence emerges according to the CHEST guideline policies.<sup>6</sup>

The PICO questions and guideline statements are separated into four broad categories, which reflect the patient groups assessed in clinical practice:

- Patients receiving a VKA, focused on warfarin.
- Among patients receiving a VKA, the use of perioperative heparin bridging.
- Patients receiving a DOAC.
- Patients receiving an antiplatelet drug.

The PICO questions are further arranged to reflect practical aspects of perioperative antithrombotic management, which includes:

- Interruption and resumption of VKAs before and after an elective surgery/procedure and need for perioperative heparin bridging.
- For patients in whom heparin bridging is considered, how to manage pre- and post-operative bridging during VKA interruption.

---

**AFFILIATIONS:** From the Department of Medicine (J. D. D.), St. Joseph's Healthcare Hamilton and McMaster University, Hamilton, ON, Canada; Department of Medicine (A. C. S.), Northwell Health at Lenox Hill Hospital, New York, NY; the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell (A. C. S.), Hempstead, NY; Institute of Health Systems Science at The Feinstein Institutes for Medical Research (A. C. S.), Manhasset, NY; Mayo Clinic Evidence-Based Practice Center (M. H. M. and S. H. S.), Rochester, MN; Department of Surgery (J. I. A.), Facultad de Medicina, University of Granada, Granada, Spain; Department of Pharmacy (W. E. D.), University of California-Davis, Sacramento, CA; Division of Hospital Medicine (A. S. D.), Department of Medicine, Mt. Sinai Health System, New York, NY; Department of Internal Medicine (R. A. F.), Loma Linda University Medical Center, Loma Linda, CA; Department of Internal Medicine (R. A. F.), Riverside University Health System Medical Center, Moreno Valley, CA; Department of Anesthesiology, Critical Care, and Surgery (Cardiothoracic) (J. H. L.), Duke University School of Medicine, Durham, NC; Department of Anaesthesia, Intensive Care and Perioperative Medicine (C. M. S.), GHU AP-HP, Centre-Université Paris-Cité-Cochin Hospital, Paris, France; Inova Heart and Vascular Institute (M. W. S.), Falls Church, VA; Department of Medicine (A. J. T.), Cardiovascular, NorthShore University HealthSystem, Evanston, IL; Institute of Hematology (L. V. T.), Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, China; and the F. Edward Hébert School of Medicine (L. K. M.), Uniformed Services University of the Health Sciences, Bethesda, MD.

Drs Douketis and Spyropoulos served as co-primary authors.

**Disclaimer:** American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at <https://www.chestnet.org/Guidelines-and-Resources>.

**CORRESPONDENCE TO:** James D. Douketis, MD, FCCP; email: [jdouket@mcmaster.ca](mailto:jdouket@mcmaster.ca)

Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

**DOI:** <https://doi.org/10.1016/j.chest.2022.08.004>

- Interruption and resumption of DOACs before and after an elective surgery/procedure.
- Perioperative management of antiplatelet therapy around non-cardiac surgery, cardiac surgery (mainly coronary artery bypass graft [CABG] surgery), and in patients with cardiac stents.
- Management of VKAs, DOACs, and antiplatelet drugs around minor procedures, comprising dental, dermatologic, ophthalmologic, GI endoscopy, and cardiac device implantation (pacemakers and internal cardiac defibrillators [ICDs]).

Qualifying remarks and definition of terms:

- This guideline addresses the perioperative antithrombotic management of patients who require an elective, non-urgent, surgery/procedure; it does not address patients who require an urgent surgery/procedure in whom the management paradigm differs considerably from that in the elective clinical setting.<sup>7</sup>
- This guideline addresses the management of patients who are receiving long-term, typically  $\geq 3$  months, antithrombotic therapy and focuses on the most commonly used VKAs (warfarin), DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), and antiplatelet drugs (aspirin [ASA], clopidogrel, prasugrel, ticagrelor); it does not address the management of drugs with anticoagulant or antiplatelet properties that are used infrequently (eg, cilostazol, dipyridamole, pentoxifylline) or that are used, typically, for short periods (eg, nonsteroidal antiinflammatory drugs).
- Perioperative antithrombotic management is anchored on the assessment of thromboembolic and bleeding risk based on patient- and surgery/procedure-related factors; this guideline provides risk classification schemes for thromboembolism and bleeding that are empiric but can aid patient management.
- The “perioperative period” or “perioperatively” is defined as the period focused before and after a surgery/procedure but, in its entirety, spans from 1 week before until 4 weeks after a surgery/procedure.<sup>8</sup>
- “Heparin bridging” is defined as the pre- and/or post-operative administration of a therapeutic-dose regimen of low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH), focusing on LMWH bridging, which is the most widely studied regimen and has the greatest potential for benefit (reduced thromboembolism) and potential trade-off of harm (increased bleeding).<sup>4,5</sup>

## Notes on Guideline Methodology

Certainty of evidence was based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach and is categorized as high, moderate, low, or very low.<sup>9</sup> Overall, evidence synthesis comprised direct evidence related to the PICO question and indirect evidence, the later especially when indirect evidence was limited. In the absence of high-quality evidence, it must be emphasized that providers will need to conduct an individualized assessment of patient-related as well as procedural-related risk factors for bleeding and thrombosis to finalize any perioperative antithrombotic strategy based on these factors.

## Perioperative Antithrombotic Management Care Pathways


Based on the evidence presented, perioperative antithrombotic patient care pathways are shown in [Figure 1](#), [Figure 2](#), and [Figure 3](#). These pathways can be used to inform individual patient management and to develop standardized care paths for clinics or institutions. [Figure 1](#) pertains to patients receiving a VKA and provides guidance on whether to interrupt VKA therapy perioperatively (if interruption is needed), how to interrupt VKA pre-operatively, whether to use heparin bridging therapy and how to bridge, and how to restart VKA and bridging therapy (if used) post-operatively. [Figure 2](#) pertains to patients receiving a DOAC and provides guidance on whether to interrupt DOAC therapy perioperatively, and if interruption is needed, how to interrupt DOAC therapy based on surgical/procedural bleed risk in the pre- and post-operative period. [Figure 3](#) pertains to patients who are receiving antiplatelet therapy and provides guidance on the timing of perioperative interruption based on the type of antiplatelet agent (ie, aspirin, clopidogrel, prasugrel, ticagrelor).

### *Section 1: Patients Who Are Receiving a VKA and Require an Elective Surgery or Procedure*

**1. In patients requiring VKA (warfarin) interruption for an elective surgery/procedure, we suggest stopping VKAs (warfarin)  $\geq 5$  days over an interruption of  $< 5$  days before an elective surgery/procedure** (Conditional Recommendation, Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- Providing a perioperative VKA management calendar that is distributed by paper or electronically



**Legend**

\*Warfarin can be resumed on the evening of procedure (D0) for most patients, or the day after procedure (i.e., D1) at the patient’s usual maintenance dose.

\*\*Bridging suggested for high thrombotic risk populations with full-dose, subcutaneous LMWH (e.g., enoxaparin, 1 mg/kg bid or 1.5 mg/kg daily or dalteparin, 100 IU/kg bid or 200 IU/kg daily), with the last dose given the AM of the day prior to the procedure (i.e., D-1) at half the total daily dose.

†Low-dose LMWH (e.g., enoxaparin, 40 mg daily or dalteparin 5,000 IU daily) can be used for VTE prophylaxis for first 24-72 hours post-procedure, with full dose LMWH resumed 2-3 days post-procedure.

Figure 1 – Perioperative management of vitamin K antagonists (warfarin). LMWH = low-molecular-weight heparin.

to patients and clinicians has the potential to minimize VKA dosing errors and optimize communication.

- In selected patients, especially the elderly with comorbidities, patients with very low-dose warfarin requirements, and those with a higher target international normalized ratio (INR) range, a longer period of warfarin interruption may be needed.

- The interruption timing for non-warfarin VKAs will differ, as it is shorter for acenocoumarol (2-3 days) and longer for phenprocoumon (10-12 days).


**2. In patients requiring VKA (warfarin) interruption for an elective surgery/procedure, we suggest resuming VKA (warfarin) within 24 hours over a delay to > 24 hours after an elective surgery/procedure (Conditional Recommendation, Low Certainty of Evidence).**

Direct Oral Anticoagulant	Procedure Bleeding Risk	Pre-Procedure DOAC Interruption						Surgery/Procedure (Day 0)	Post-Procedure Resumption*			
		Day -6	Day -5	Day -4	Day -3	Day -2	Day -1		Day +1	Day +2	Day +3	Day +4
Apixaban	High	[Red arrow from Day -6 to Day -1]						Surgery/Procedure (Day 0)	[Red arrow from Day +1 to Day +4]			
	Low/Mod	[Red arrow from Day -6 to Day -1]							[Red arrow from Day +1 to Day +4]			
Dabigatran (CrCl ≥ 50 ml/min)	High	[Blue arrow from Day -6 to Day -1]							[Blue arrow from Day +1 to Day +4]			
	Low/Mod	[Blue arrow from Day -6 to Day -1]							[Blue arrow from Day +1 to Day +4]			
Dabigatran (CrCl < 50 ml/min)	High	[Grey arrow from Day -5 to Day -1]	[Grey arrow from Day -6 to Day -1]						[Grey arrow from Day +1 to Day +4]			
	Low/Mod	[Grey arrow from Day -6 to Day -1]							[Grey arrow from Day +1 to Day +4]			
Edoxaban	High	[Orange arrow from Day -6 to Day -1]							[Orange arrow from Day +1 to Day +4]			
	Low/Mod	[Orange arrow from Day -6 to Day -1]							[Orange arrow from Day +1 to Day +4]			
Rivaroxaban	High	[Cyan arrow from Day -6 to Day -1]						[Cyan arrow from Day +1 to Day +4]				
	Low/Mod	[Cyan arrow from Day -6 to Day -1]						[Cyan arrow from Day +1 to Day +4]				

[Yellow box] No DOAC administered that day

\*DOAC can be resumed ~24 hours after low/moderate-bleed-risk procedures, and 48-72 hours after high-bleed-risk procedures. In selected patients at high risk for VTE, low-dose anticoagulants (i.e., enoxaparin, 40 mg daily or dalteparin, 5,000 IU daily) can be given for the first 48-72 hours post-procedure.

Figure 2 – Perioperative management of direct oral anticoagulants (DOACs). CrCl = creatinine clearance.



**Legend:**

\*Based on surgery/procedure bleed risk assessment.

\*\*Routine use not suggested. If used, initiate within 72 hours from P2Y<sub>12</sub> inhibitor discontinuation at dose of 0.75 mg/kg/min; resume within 6 hours post-procedure for minimum of 48 hours and maximum of 7 days total. Very low quality data for antiplatelet bridging with glycoprotein IIb/IIIa inhibitors (e.g., eptifibatid, tirofiban).

\*\*\*P2Y<sub>12</sub> inhibitors can be resumed within 24 hours post-procedure at a maintenance dose.

†For ticagrelor, 3-5 day interruption

††For clopidogrel, 5 day interruption

§For prasugrel, 7-10 day interruption.

Figure 3 – Perioperative management of antiplatelet drugs. ASA = aspirin.

*Guideline Implementation Considerations:*

- For most patients, resuming VKAs within 24 hours implies resumption on the evening of the surgery/procedure.
- Implicit in the early (within 24 hours) resumption of a VKA is that it takes, typically, 2 to 3 days for a partial anticoagulant effect and 4 to 8 days for a full anticoagulant effect to occur.
- VKA resumption may be delayed in certain post-operative circumstances, such as inadequate surgery/procedure-site hemostasis, an anticipated need for additional intervention, or patient inability to take oral medications.

**3. In patients requiring VKA (warfarin) interruption for an elective surgery/procedure, we suggest resuming the first post-operative VKA dose at the patient’s usual dose over resuming VKA with double the usual dose (Conditional Recommendation, Very Low Certainty of Evidence).**

*Guideline Implementation Considerations:*

- Although post-operative doubling of the warfarin dose for 1 to 2 days may lead to a more rapid attainment of an INR  $\geq 2.0$  in some patients, there are concerns in applying this approach in practice; for example, in

patients with variable warfarin dose regimens and those expected to be hospitalized for > 1 day.

**4. In patients requiring VKA interruption for an elective surgery/procedure who have an elevated INR (ie, > 1.5) 1 to 2 days before the surgery/procedure, we suggest against routine use of pre-operative vitamin K (Conditional Recommendation, Very Low Certainty of Evidence).**

*Guideline Implementation Considerations:*

- Uncertainty about routine pre-operative vitamin K administration relates to the dose of vitamin K, limited availability of oral vitamin K formulations, and potential for resistance to post-operative re-anticoagulation.

**5. In patients receiving VKA therapy for a mechanical heart valve who require VKA interruption for an elective surgery/procedure, we suggest against heparin bridging (Conditional Recommendation, Very Low Certainty of Evidence).**

*Guideline Implementation Considerations:*

- In selected patients considered at high risk for thromboembolism (Table 1), as examples, those with (1) an older-generation mechanical heart valve



[ie, tilting-disc valve]; (2) a mechanical mitral valve with one or more risk factors for stroke; (3) a recent (< 3 months) thromboembolic event; or (4) other high-risk patients (eg, prior perioperative stroke), pre- and post-operative heparin bridging is suggested (see Guideline Statement 8).

**6. In patients receiving VKA therapy for atrial fibrillation who require VKA interruption for an elective surgery/procedure, we recommend against heparin bridging** (Strong Recommendation, Moderate Certainty of Evidence).

*Guideline Implementation Considerations:*

- In selected patients considered at high risk for thromboembolism (Table 1), as examples (1) those with a recent [ $< 3$  month] history of stroke or transient ischemic attack; (2) other high-risk patients (eg, prior perioperative stroke); or (3) with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 7$  or CHADS<sub>2</sub> score of 5 or 6), pre- and post-operative heparin bridging is suggested (see Guideline Statement 8).
- A perioperative VKA and heparin bridging calendar (paper or electronic) that provides patients and clinicians an easy-to-use timetable for VKA interruption and resumption alongside the heparin bridging dosing regimen has the potential to minimize errors and optimize communication among caregivers.

**7. In patients receiving VKA therapy for VTE as the sole clinical indication who require VKA interruption for an elective surgery/procedure, we suggest against heparin bridging** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- Suggesting against bridging with a therapeutic-dose heparin regimen does not preclude the empiric use of a low-dose heparin regimen, typically started within 24 hours after surgery and continued for up to 5 days while VKA therapy is resumed, to decrease the risk for post-operative VTE.
- In selected patients considered at high risk for VTE (Table 1), as examples (1) those with a recent (< 3 months) history of VTE, or (2) severe thrombophilia, or (3) selected types of active cancer, pre- and post-operative heparin bridging is suggested (see Guideline Statement 8).

**8. In patients receiving VKA therapy who are classified as high risk for thromboembolism and who**

**require VKA interruption for an elective surgery/procedure, we suggest heparin bridging over no heparin bridging** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- Stratification of patients according to perioperative thromboembolic risk, as shown in Table 1, is empiric as there are no clinical prediction models that have been validated in this clinical setting. Accordingly, a patient's individual risk profile may inform decisions about heparin bridging. The type of surgery may also affect thromboembolic risk; for example, an anticipated higher risk in patients having open cardiac or major vascular surgery.

**9. In patients receiving VKA therapy who are classified as low-to-moderate-risk for thromboembolism and who require VKA interruption for an elective surgery/procedure, we suggest against heparin bridging** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- Although patients may be classified empirically as low-to-moderate-risk for thromboembolism, there may be selected patients within this classification grouping (Table 1) in whom heparin bridging may be considered.

### Management of VKAs Around Minor Procedures (Dental, Dermatologic, Ophthalmologic, Pacemaker/ICD, Colonoscopy With/Without Polypectomy)

**10. In patients receiving VKA therapy who need a dental procedure, we suggest continuation of VKA over VKA interruption** (Conditional Recommendation, Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- The risk for dental procedure-related bleeding may vary, being lower with single tooth extractions and higher with multiple tooth extractions or in patients with poor gingival health; accordingly, VKA interruption may be preferred in situations where oral bleeding is expected to be considerable.

**11. In patients receiving VKA therapy who need a dental procedure, we suggest using a pro-hemostatic agent with continuation of VKA over alternative management options (eg, discontinuation of VKA**

**TABLE 1 ]** Adapted American College of Chest Physicians (CHEST) Suggested Risk Stratification for Patient-Specific Periprocedural Thromboembolism<sup>4,5,8</sup>

Risk Category	Mechanical Heart Valve	Atrial Fibrillation	VTE
High (> 10%/y risk of ATE or > 10%/mo risk of VTE)	Mitral valve with major risk factors for stroke <sup>b</sup> Caged ball or tilting-disc valve in mitral/aortic position Recent (< 3 mo) stroke or TIA or other high-risk stroke situations <sup>c</sup>	CHA <sub>2</sub> DS <sub>2</sub> VASc score of ≥ 7 or CHADS <sub>2</sub> score of 5 or 6 Recent (< 3 mo) stroke or TIA Rheumatic valvular heart disease	Recent (< 3 mo and especially 1 mo) VTE Severe thrombophilia (deficiency of protein C, protein S or antithrombin; homozygous factor V Leiden or prothrombin gene G20210A mutation or double heterozygous for each mutation, multiple thrombophilias) Antiphospholipid antibodies Active cancer associated with high VTE risk <sup>a</sup>
Moderate (4%-10%/y risk of ATE or 4%-10%/mo risk of VTE)	Bileaflet AVR <i>with</i> major risk factors for stroke <sup>b</sup>	CHA <sub>2</sub> DS <sub>2</sub> VASc score of 5 or 6 or CHADS <sub>2</sub> score of 3 or 4	VTE within past 3-12 mo Recurrent VTE Non-severe thrombophilia (heterozygous factor V Leiden or prothrombin gene G20210A mutation) Active cancer or recent history of cancer <sup>c</sup>
Low (< 4%/y risk of ATE or < 2%/mo risk of VTE)	Bileaflet AVR <i>without</i> major risk factors for stroke <sup>b</sup>	CHA <sub>2</sub> DS <sub>2</sub> VASc score of 1-4 or CHADS <sub>2</sub> score of 0-2 (and no prior stroke or TIA)	VTE > 12 mo ago

This was an empiric risk classification, not prospectively validated. ATE = arterial thromboembolism; AVR = aortic valve replacement; CHADS<sub>2</sub> = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack; CHA<sub>2</sub>DS<sub>2</sub>VASc = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease history, age ≥ 65 years, female sex.

<sup>a</sup>Includes pancreatic cancer, myeloproliferative disorders, primary brain cancer, gastric cancer, and esophageal cancer.

<sup>b</sup>Includes multiple prior strokes, prior perioperative stroke, or prior valve thrombosis.

<sup>c</sup>Atrial fibrillation, prior stroke or transient ischemic attack (TIA), hypertension, diabetes, congestive heart failure, and age > 75 years.

**with or without heparin bridging** (Conditional Recommendation, Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- Pro-hemostatic options include pre- and post-procedure administration of oral tranexamic acid mouthwash, two to three times daily, and intervention-specific measures (eg, extra sutures, gauze soaked in tranexamic acid).

**12. In patients receiving VKA therapy who require a minor dermatologic procedure, we suggest continuation of VKA over VKA interruption** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- The risk for dermatologic procedure-related bleeding may vary, being lower with resections of small (1-2 cm) skin cancers and biopsies, and higher with resections of larger (> 3 cm) skin cancers, particularly if skin grafting is required; accordingly, VKA interruption may be preferred in situations where site-related bleeding is expected to be considerable or if lengthy wound healing is expected (eg, skin graft).

**13. In patients receiving VKA therapy who require a minor ophthalmologic procedure, we suggest continuation of VKA over VKA interruption** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- VKA interruption may be preferred in patients considered at higher risk for bleeding; for example, those having more complex retinal surgery or patients having surgery with retrobulbar anesthesia. Cataract surgery is done usually with topical anesthesia and, less commonly, with retrobulbar anesthesia.

**14. In patients receiving VKA therapy who require a pacemaker or ICD implantation, we recommend continuation of VKA over VKA interruption and heparin bridging** (Strong Recommendation, Moderate Certainty of Evidence).

*Guideline Implementation Considerations:*

- Continuation of VKAs around cardiac device procedures is based on the premise that the patient's INR at the time of the procedure is < 3.0.

**15. In patients receiving VKA therapy who require VKA interruption for a colonoscopy with anticipated polypectomy, we suggest against heparin bridging during the period of VKA interruption** (Conditional Recommendation, Very Low Certainty of Evidence).

### *Section 2: Perioperative Management of Patients Who Are Receiving Heparin Bridging*

**16. In patients receiving therapeutic-dose IV UFH bridging for an elective surgery/procedure, we suggest stopping UFH  $\geq 4$  hours before a surgery/procedure over stopping IV UFH  $< 4$  hours before a surgery/procedure** (Conditional Recommendation, Very Low Certainty of Evidence).

**17. In patients receiving therapeutic-dose IV UFH bridging for an elective surgery/procedure, we suggest resuming UFH  $\geq 24$  hours after a surgery/procedure over resuming UFH within 24 hours after a surgery/procedure** (Conditional Recommendation, Very Low Certainty of Evidence).

#### *Guideline Implementation Considerations:*

- When resuming UFH post-operatively, we suggest avoiding a bolus dose and commencing with a lower-intensity infusion that is associated with a lower target activated partial thromboplastin time than that used for initiation of full-dose UFH administration.

**18. In patients receiving LMWH bridging for an elective surgery/procedure, we suggest administering the last pre-operative LMWH bridging dose at approximately 24 hours over administering the last dose 10 to 12 hours before a surgery/procedure** (Conditional Recommendation, Very Low Certainty of Evidence).

**19. In patients receiving LMWH bridging for an elective surgery/procedure, we suggest administering the first post-operative LMWH bridging dose at least 24 hours after a surgery/procedure over administering it less than 24 hours after a surgery/procedure** (Conditional Recommendation, Very Low Certainty of Evidence).

#### *Guideline Implementation Considerations:*

- We suggest waiting at least 24 hours before resuming LMWH bridging in patients having a low-to-moderate-bleed-risk surgery/procedure and waiting at least 48 to 72 hours before resuming LMWH bridging in patients having a high-bleed-risk surgery/procedure (Table 2).

- For patients in whom the management plan is to delay resumption of LMWH bridging for 48 to 72 hours and who are considered at high risk for post-operative VTE, low-dose LMWH can be administered for the initial 2 to 3 days before the transition to LMWH bridging.

**20. In patients receiving LMWH bridging for an elective surgery/procedure, we suggest administering half the total daily dose of LMWH the day prior to the surgery/procedure over administering the full dose of LMWH the day prior** (Conditional Recommendation, Very Low Certainty of Evidence).

#### *Guideline Implementation Considerations:*

- This guidance may apply more to patients having a high-bleed-risk surgery, including patients having neuraxial (spinal or epidural) anesthesia, rather than in patients having a low-to-moderate-bleed-risk surgery/procedure (Table 2).
- Administering half the total daily dose of LMWH can be done by giving, on the morning of the day before the surgery/procedure, only the morning dose of a twice-daily LMWH regimen or approximately 50% of the dose of a once-daily LMWH regimen.

**21. In patients receiving LMWH bridging for an elective surgery/procedure, we suggest against routine measurement of anti-factor Xa levels to guide perioperative LMWH management** (Conditional Recommendation, Very Low Certainty of Evidence).

#### *Guideline Implementation Considerations:*

- There may be select patients undergoing high-bleed-risk surgeries/procedures (ie, intracranial, spinal) or patients who require an urgent (non-elective) surgery/procedure where anti-factor Xa measurement may be considered.

### *Section 3: Patients Who Are Receiving a DOAC and Require an Elective Surgery/Procedure*

**22. In patients receiving apixaban who require an elective surgery/procedure, we suggest stopping apixaban for 1 to 2 days before the surgery/procedure over apixaban continuation** (Conditional Recommendation, Very Low Certainty of Evidence).

#### *Guideline Implementation Considerations:*

- The number of days of pre-operative apixaban interruption before the surgery/procedure will depend on the bleed risk associated with the surgery/procedure:
  - o 1 day off before low-to-moderate-bleed-risk;
  - o 2 days off before high-bleed-risk.



**TABLE 2 ] Suggested Risk Stratification for Procedural Bleed Risk Based on ISTH Guidance Statements<sup>8</sup>**

<p>High-bleed-risk surgery/procedure<sup>a</sup> (30-d risk of major bleed <math>\geq</math> 2%)</p>	<p>Major surgery with extensive tissue injury            Cancer surgery, especially solid tumor resection (lung, esophagus, gastric, colon, hepatobiliary, pancreatic)            Major orthopedic surgery, including shoulder replacement surgery            Reconstructive plastic surgery            Major thoracic surgery            Urologic or GI surgery, especially anastomosis surgery            Transurethral prostate resection, bladder resection, or tumor ablation            Nephrectomy, kidney biopsy            Colonic polyp resection            Bowel resection            Percutaneous endoscopic gastrostomy placement, endoscopic retrograde cholangiopancreatography            Surgery in highly vascular organs (kidneys, liver, spleen)            Cardiac, intracranial, or spinal surgery            Any major operation (procedure duration &gt; 45 min)            Neuraxial anesthesia<sup>b</sup>            Epidural injections</p>
<p>Low-to-moderate-bleed-risk surgery/procedure<sup>c</sup> (30-d risk of major bleed 0%-2%)</p>	<p>Arthroscopy            Cutaneous/lymph node biopsies            Foot/hand surgery            Coronary angiography<sup>d</sup>            GI endoscopy <math>\pm</math> biopsy            Colonoscopy <math>\pm</math> biopsy            Abdominal hysterectomy            Laparoscopic cholecystectomy            Abdominal hernia repair            Hemorrhoidal surgery            Bronchoscopy <math>\pm</math> biopsy</p>
<p>Minimal-bleed-risk surgery/procedure<sup>e</sup> (30-d risk of major bleed approximately 0%)</p>	<p>Minor dermatologic procedures (excision of basal and squamous cell skin cancers, actinic keratoses, and premalignant or cancerous skin nevi)            Ophthalmologic (cataract) procedures            Minor dental procedures (dental extractions, restorations, prosthetics, endodontics), dental cleanings, fillings            Pacemaker or cardioverter-defibrillator device implantation</p>

ISTH = International Society on Thrombosis and Haemostasis.

<sup>a</sup>Minimal to no residual anticoagulant effect at time of procedure (ie, four to five drug half-life interruptions pre-procedure).

<sup>b</sup>Includes spinal and epidural anesthesia or any other neuraxial (eg, pain management) intervention; consider not only absolute risk for major bleeding but potentially devastating consequences of epidural bleeding and associated lower limb paralysis.

<sup>c</sup>Some residual anticoagulant effect allowed (ie, two to three drug half-life interruptions pre-procedure).

<sup>d</sup>Radial approach may be considered minimal-bleed-risk compared with femoral approach.

<sup>e</sup>Procedure can be safely done under full-dose anticoagulation (may consider holding DOAC dose day of procedure to avoid peak anticoagulant effects).

- This management may be applied irrespective of whether patients are receiving apixaban for atrial fibrillation or VTE.

**23. In patients receiving dabigatran who require an elective surgery/procedure, we suggest stopping dabigatran for 1 to 4 days before the surgery/procedure over dabigatran continuation** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- The number of days of pre-operative dabigatran interruption before the surgery/procedure will depend on the bleed risk associated with the surgery/procedure and patient renal function:
  - o 1 day off before low-to-moderate-bleed-risk if creatinine clearance (CrCl)  $\geq$  50 mL/min;
  - o 2 days off before low-to-moderate-bleed-risk if CrCl < 50 mL/min;
  - o 2 days off before high-bleed-risk if CrCl  $\geq$  50 mL/min;
  - o 4 days off for high-bleed-risk if CrCl < 50 mL/min (this extended duration of interruption of > 2 days reflects the unique management of patients who are receiving dabigatran and have a CrCl < 50 mL/min).
- This management may be applied irrespective of whether patients are receiving dabigatran for atrial fibrillation or VTE.

**24. In patients receiving edoxaban who require an elective surgery/procedure, we suggest stopping edoxaban for 1 to 2 days before the surgery/procedure over edoxaban continuation** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- The number of days of pre-operative edoxaban interruption before the surgery/procedure will depend on the bleed risk associated with the surgery/procedure:
  - o 1 day off before low-to-moderate-bleed-risk;
  - o 2 days off before high-bleed-risk.
- This management may be applied irrespective of whether patients are receiving edoxaban for atrial fibrillation or VTE.

**25. In patients receiving rivaroxaban who require an elective surgery/procedure, we suggest stopping rivaroxaban for 1 to 2 days before the surgery/procedure over rivaroxaban continuation** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- The number of days of pre-operative rivaroxaban interruption before the surgery/procedure will depend on the bleed risk associated with the surgery/procedure:
  - o 1 day off before low-to-moderate-bleed-risk;
  - o 2 days off before high-bleed-risk.
- This management may be applied irrespective of whether patients are receiving rivaroxaban for atrial fibrillation or VTE.

**26. In patients who require DOAC interruption for an elective surgery/procedure, we suggest against perioperative heparin bridging** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- The rapid offset and rapid onset of action of DOACs obviates the need for heparin bridging with short-acting anticoagulants such as UFH or LMWH in a perioperative setting.

**27. In patients who had DOAC interruption for an elective surgery/procedure, we suggest resuming DOACs > 24 hours after a surgery/procedure over resuming DOACs within 24 hours** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- The resumption of DOACs post-operatively will depend on the bleed risk associated with the surgery/procedure:

- o at least 24 hours after low-to-moderate-bleed-risk;
- o 48 to 72 hours after high-bleed-risk.

- DOACs have a rapid onset of action, with a peak effect occurring 1 to 3 hours after intake, thereby requiring cautious administration after a surgery/procedure.

**28. In patients who had DOAC interruption for an elective surgery/procedure, we suggest against routine DOAC coagulation function testing to guide perioperative DOAC management** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- DOAC level testing may be considered, on a case-by-case basis, in non-elective perioperative clinical situations; for example, in patients who require an urgent/emergency surgery/procedure in whom DOAC level testing may inform the need for active DOAC reversal with administration of blood products or DOAC-specific reversal agents.

#### *Section 4: Perioperative Management of Patients Who Are Receiving Antiplatelet Drugs*

**29a. In patients receiving ASA who are undergoing elective non-cardiac surgery, we suggest ASA continuation over ASA interruption** (Conditional Recommendation, Moderate Certainty of Evidence).

*Guideline Implementation Considerations:*

- This guidance may be modified on a case-by-case basis; for example, in select patients undergoing a non-cardiac surgery associated with a high-bleed-risk (eg, intracranial, spinal). If ASA interruption is adopted, we suggest interruption for  $\leq 7$  days.

**29b. In patients receiving ASA therapy who are undergoing elective surgery and require ASA interruption, we suggest stopping ASA  $\leq 7$  days instead of 7 to 10 days before the surgery** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- This suggestion may be modified on a case-by-case basis, depending on individual patient circumstances; for example, surgery-related bleeding risk.

**30. In patients receiving clopidogrel who are undergoing an elective non-cardiac surgery, we suggest stopping clopidogrel 5 days instead of 7 to 10 days before the surgery** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- This suggestion may be modified on a case-by-case basis, depending on individual patient circumstances; for example, surgery-related bleeding risk.

**31. In patients receiving ticagrelor who are undergoing an elective non-cardiac surgery, we suggest stopping ticagrelor 3 to 5 days instead of 7 to 10 days before the surgery** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- This suggestion may be modified on a case-by-case basis, depending on individual patient circumstances; for example, surgery-related bleeding risk.

**32. In patients receiving prasugrel who are undergoing an elective non-cardiac surgery, we suggest stopping prasugrel 7 days instead of 7 to 10 days before the surgery** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- This suggestion may be modified on a case-by-case basis, depending on individual patient circumstances; for example, surgery-related bleeding risk.

**33. In patients who require antiplatelet drug interruption for an elective surgery/procedure, we suggest to resume antiplatelet drugs  $\leq$  24 hours instead of  $>$  24 hours after the surgery/procedure** (Conditional Recommendation, Very Low Certainty of Evidence).

**34. In patients who are receiving ASA and undergoing CABG surgery, we suggest continuation of ASA over interruption; in patients receiving a P2Y<sub>12</sub> inhibitor drug, we suggest interruption of the P2Y<sub>12</sub> inhibitor over continuation perioperatively** (Conditional Recommendation, Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- For pre-operative P2Y<sub>12</sub> interruption, prior to the day of surgery/procedure, we suggest:
  - 7 days for prasugrel;
  - 5 days for clopidogrel;
  - 3 to 5 days for ticagrelor.

**35. In patients receiving ASA or a P2Y<sub>12</sub> inhibitor who are undergoing CABG surgery, we suggest resuming the ASA or the P2Y<sub>12</sub> inhibitor within 24 hours after surgery compared with  $\geq$  24 hours after surgery** (Conditional Recommendation, Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- Resumption of antiplatelet therapy may be delayed in patients who develop post-CABG thrombocytopenia (platelet count  $<$  50,000  $\times$  10<sup>9</sup>/L), typically occurring with on-pump surgery.

**36. In patients receiving antiplatelet drug therapy who are undergoing an elective surgery/procedure, we suggest against the routine use of platelet function testing prior to the surgery/procedure to guide perioperative antiplatelet management** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- Platelet function testing could be used with a possible small benefit and little harm in certain scenarios such as patients undergoing CABG surgery who have recently started taking a P2Y<sub>12</sub> inhibitor. Costs would be moderate for implementation.

**37. In patients receiving ASA and a P2Y<sub>12</sub> inhibitor with coronary stents placed within the last 6 to 12 weeks who are undergoing an elective surgery/procedure, we suggest either continuation of both antiplatelet agents or stopping one antiplatelet agent within 7 to 10 days of surgery** (Conditional Recommendation, Very Low Certainty of Evidence).

*Guideline Implementation Considerations:*

- Either approach is reasonable depending on the bleeding risk associated with the surgery/procedure if antiplatelet therapy is continued and risk for acute coronary syndrome/coronary stent thrombosis if antiplatelet therapy is interrupted.
- Several factors will weigh in the decision about whether to continue dual antiplatelet therapy or interrupt one agent, including: the timing of stent placement (whether closer to 6 weeks or 12 weeks); the type of stent (drug-eluting or bare-metal); the location of the stent (whether at a dominant coronary artery or not); and the number and length of stents implanted.

**38. In patients receiving ASA and a P2Y<sub>12</sub> inhibitor who had coronary stents placed within the last 3 to 12 months and are undergoing an elective surgery/procedure, we suggest stopping the P2Y<sub>12</sub> inhibitor prior to surgery over continuation of the P2Y<sub>12</sub> inhibitor** (Conditional Recommendation, Very Low Certainty of Evidence).

### Guideline Implementation Considerations:

- This guidance is based on indirect evidence and expert-based consensus that stopping P2Y<sub>12</sub> inhibitors in patients with stents > 3 months' post-implantation is likely safe.
- Several factors will weigh in the decision about whether to continue or interrupt the P2Y<sub>12</sub> inhibitor, including: the timing of stent placement (whether closer to 3 months or 12 months); the type of stent (drug-eluting or bare-metal); the location of the stent (whether at a dominant coronary artery or not); and the number and length of stents implanted.

**39. In patients with coronary stents who require interruption of antiplatelet drugs for an elective surgery/procedure, we suggest against routine bridging therapy with a glycoprotein IIb/IIIa inhibitor, cangrelor, or LMWH over routine use of bridging therapy** (Conditional Recommendation, Low Certainty of Evidence).

### Guideline Implementation Considerations:

- A bridging approach may be considered in selected high-risk patients; for example, in those with a recent (within 3 months) coronary stent in a critical location.

**40. In patients with coronary stents who require continued dual antiplatelet therapy, we suggest delaying an elective surgery/procedure over not delaying the surgery/procedure** (Conditional Recommendation, Very Low Certainty of Evidence).

### Guideline Implementation Considerations:

- The duration of surgery/procedure delay is addressed on a case-by-case basis and should consider the urgency of the surgery/procedure, the time elapsed since coronary stenting, and the risk profile of the coronary stenting (eg, critical location, multiple stents).
- Regarding the timing of cessation of P2Y<sub>12</sub> inhibitors or ASA, we refer to Guideline Statements 29a/b through 33.

## Management of Antiplatelet Drugs Around Minor Procedures (Dental, Dermatologic, Ophthalmologic)

**41. In patients receiving an antiplatelet drug (ASA or P2Y<sub>12</sub> inhibitor) who are undergoing a minor dental procedure, we suggest continuing the antiplatelet drug (ASA or P2Y<sub>12</sub> inhibitor) over stopping the antiplatelet agent before the procedure** (Conditional Recommendation, Very Low Certainty of Evidence).

### Guideline Implementation Considerations:

- Patients who are receiving dual antiplatelet therapy with ASA and a P2Y<sub>12</sub> inhibitor can continue ASA and interrupt the P2Y<sub>12</sub> inhibitor.

**42. In patients receiving an antiplatelet drug (ASA or P2Y<sub>12</sub> inhibitor) who are undergoing a minor dermatologic procedure, we suggest continuing the antiplatelet drug (ASA or P2Y<sub>12</sub> inhibitor) over stopping the antiplatelet agent before the procedure** (Conditional Recommendation, Very Low Certainty of Evidence).

### Guideline Implementation Considerations:

- Patients who are receiving dual antiplatelet therapy with ASA and a P2Y<sub>12</sub> inhibitor can continue ASA and interrupt the P2Y<sub>12</sub> inhibitor.

**43. In patients receiving an antiplatelet drug (ASA or P2Y<sub>12</sub> inhibitor) undergoing a minor ophthalmologic procedure, we suggest continuing the antiplatelet drug (ASA or P2Y<sub>12</sub> inhibitor) throughout the ophthalmologic procedure over stopping the antiplatelet agent before the procedure** (Conditional Recommendation, Low Certainty of Evidence).

### Guideline Implementation Considerations:

- Patients who are receiving dual antiplatelet therapy with ASA and a P2Y<sub>12</sub> inhibitor can continue ASA and interrupt the P2Y<sub>12</sub> inhibitor.

## Acknowledgments

**Author contributions:** J. D. D. and A. C. S. served as the co-principal authors; all authors contributed to the development of the guideline methodology, analysis of evidence and writing of the manuscript.

**Funding/support:** The authors have reported to *CHEST* that no funding was received for this study.

**Financial/nonfinancial disclosure:** A complete list of the panelists' COI and their management is shown in [e-Appendix 1](#).

## References

1. Williams BA, Honushefsky AM, Berger PB. Temporal trends in the incidence, prevalence, and survival of patients with atrial fibrillation from 2004 to 2016. *Am J Cardiol*. 2017;120(11):1961-1965.
2. Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. *Int J Clin Pract*. 2018;72(3):e13070.
3. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. *Circulation*. 2012;126(3):343-348.
4. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(suppl 6):299S-339S.
5. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(suppl 2):e326S-e350S.

6. Lewis SZ, Diekemper R, Ornelas J, Casey KR. Methodologies for the development of CHEST guidelines and expert panel reports. *Chest*. 2014;146(1):182-192.
7. Douketis JD, Healey JS, Brueckmann M, et al. Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial. *Thromb Res*. 2016; 139:77-81.
8. Spyropoulos AC, Brohi K, Caprini J, et al. Scientific and Standardization Committee Communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. *J Thromb Haemost*. 2019;17(11):1966-1972.
9. Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. *BMJ*. 2016;353:i2089.